GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast A/S (CHIX:COLOBc) » Definitions » EV-to-EBITDA

Coloplast A/S (CHIX:COLOBC) EV-to-EBITDA : 26.18 (As of May. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Coloplast A/S EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coloplast A/S's enterprise value is kr213,824 Mil. Coloplast A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr8,168 Mil. Therefore, Coloplast A/S's EV-to-EBITDA for today is 26.18.

The historical rank and industry rank for Coloplast A/S's EV-to-EBITDA or its related term are showing as below:

CHIX:COLOBc' s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.75   Med: 27.15   Max: 60.69
Current: 26.18

During the past 13 years, the highest EV-to-EBITDA of Coloplast A/S was 60.69. The lowest was 15.75. And the median was 27.15.

CHIX:COLOBc's EV-to-EBITDA is ranked worse than
72.88% of 483 companies
in the Medical Devices & Instruments industry
Industry Median: 16.47 vs CHIX:COLOBc: 26.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Coloplast A/S's stock price is kr844.40. Coloplast A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr22.410. Therefore, Coloplast A/S's PE Ratio for today is 37.68.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Coloplast A/S EV-to-EBITDA Historical Data

The historical data trend for Coloplast A/S's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast A/S EV-to-EBITDA Chart

Coloplast A/S Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.92 33.81 30.68 25.28 24.13

Coloplast A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.60 27.47 24.13 24.28 28.58

Competitive Comparison of Coloplast A/S's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Coloplast A/S's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast A/S's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast A/S's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Coloplast A/S's EV-to-EBITDA falls into.



Coloplast A/S EV-to-EBITDA Calculation

Coloplast A/S's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=213823.858/8168
=26.18

Coloplast A/S's current Enterprise Value is kr213,824 Mil.
Coloplast A/S's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8,168 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast A/S  (CHIX:COLOBc) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Coloplast A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=844.40/22.410
=37.68

Coloplast A/S's share price for today is kr844.40.
Coloplast A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Coloplast A/S EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Coloplast A/S's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast A/S (CHIX:COLOBC) Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast A/S (CHIX:COLOBC) Headlines

No Headlines